Twitter | Search | |
Search Refresh
Raul Cordoba, MD, PhD 24 Mar 16
Why so high neurologic toxicity?
Reply Retweet Like
Dr. Satya Prakash Yadav May 23
HCT outcomes were analyzed in r/r ALL after salvage with Pre-HCT blina was given for morphologic (24) or MRD+ve disease (11) No unusual toxicities or delayed engraftment observed Post HCT 1 yr survival 70% It is a safe & effective salvage therapy pre-HCT
Reply Retweet Like
Anne Villeneuve-Magness, PhD 9 Jan 17
and are developing a new generation of cancer immunotherapies !
Reply Retweet Like
prIME Oncology 25 Apr 17
prIMElines—TOWER trial results show improved survival for relapsed/refractory acute lymphoblastic ...
Reply Retweet Like
Dr.Alberto Mussetti 20 Feb 19
vs SOC in R/R Ph neg BCP associated with improved HRQoL, especially after .
Reply Retweet Like
Dr George Paterakis 20 Nov 16
QUIZ (CONT) B- IN 11YRS OLD BOY PUT IN REMISSION WITH - AFTER 3 CYCLES CD19 NEGATIVE 0.17%>VOTE NEXT TWIT
Reply Retweet Like
National Cancer Institute Jan 14
Immunotherapy drug improves outcomes for some children with relapsed leukemia
Reply Retweet Like
EU Medicines Agency 7 Dec 15
Assessment report published for (), an orphan medicine for acute lymphoblastic leukaemia
Reply Retweet Like
Jennifer Smith Dec 10
constitutes a new standard of care for kids and AYAs with high- and intermediate-risk B-ALL in first relapse, according to Patrick Brown of Johns Hopkins. LBA-1 presented at .
Reply Retweet Like
Ruth York McCrea 2 Dec 18
Day 11 on which I will now call (“BMom”)- a drug with the word mom in it. How could it not be effective?! Seriously though. 👍🤓🤞
Reply Retweet Like
CastlDrs 5 May 16
Tx of older pts with relapsed/refractory B-precursor acute by
Reply Retweet Like
Phosphatidylserine 28 Jun 14
Reply Retweet Like
Paul D. Rennert 8 Mar 15
thinking about v for the treatment of relapsed refractory ALL ... I wonder
Reply Retweet Like
Amit Patel🇬🇧 Jun 16
Excellent outcomes for a systemic chemotherapy-free induction approach for (acute ), with , steroids, . As expected poor risk mutations () have more modest outcomes. Patients have gone on to
Reply Retweet Like
Sanam Loghavi, MD Oct 5
Great points. CD19 is nearly always + on untreated B-ALL, also commonly expressed by t(8;21) AML & not a marker of B cell differentiation there. Also, important:can be lost after (antiCD19) therapy in B-ALL.
Reply Retweet Like
Pharmacy Times 9 Sep 16
Now Indicated for Children with Acute Lymphoblastic
Reply Retweet Like
Oncology Board 25 Aug 16
Reply Retweet Like
Anke Holst Aug 8
Oh, with all the new info this week I forgot to announce this: my child is the patient with the best results from in the world I think? We’re starting on a third round today because of all the delays with the donor. Another month to the transplant.
Reply Retweet Like
Navneet Majhail, MD 2 Dec 16
Dr Walter symp: TOWER trial interim analysis ⬆️CR w/ vs SOC chemo
Reply Retweet Like
Dr. Satya Prakash Yadav Feb 14
Reply Retweet Like